Table 5.
Socio-demographic and clinical characteristics of the samples of studies dealing with the addition of dopamine agonists to lower prolactin.
| Reference | Country | Ethnicity | Age (years) Mean (SD) |
Duration of illness (years) Mean (SD) |
Duration of treatment with PRL-elevating antipsychotic | Substance use | Symptoms (baseline visit) |
|---|---|---|---|---|---|---|---|
| Cabergoline addition | |||||||
| Kalkavoura et al., 2013 | Greece | NR | 43.6 (9.8) | 21.8 (11.9) | NR† | Alcohol abuse was an exclusion criterion. | PANSS total: 62.9 (2.5) |
| Coronas et al., 2012 | Spain | NR | 31.2 (5.0) | NR | NR | NR | Clinical stable before starting cabergoline BPRS: 21.7 (4.9) |
| Cavallaro et al., 2004 | Italy | NR | 33.7 (5.6) | NR | >6 months | NR | NR |
| Bromocriptine addition | |||||||
| Yuan et al., 2008 | China | NR | 31.1 (7.9) | 3.2 (3.5) | >6 months | NR | NR |
| Bliesener et al., 2004 | Germany | NR | 20–45 years | NR | >4 months | NR | NR |
| Terguride addition | |||||||
| Hashimoto et al., 2014 | Japan | NR | 42.9 (10.6) | 15.0 (5.8) | 26.7 (11.9) months | NR | NR |
Abbreviations: SD= Standard deviation; NR= Not reported; CGI-S= Clinical Global Impression-Severity scale; PANSS= Positive and Negative Syndrome Scale; BPRS= Brief Psychiatric Rating Scale.
†
In the study Kalkavoura et al. (2013), patients were under antipsychotic treatment for at least 5 years before the inclusion in the study. However, it was not specified the duration of the last antipsychotic drug treatment.